[1]L Xu, A Y Hui, E Albanis, et al.Human hepatic stellate cell lines, LX-1and LX-2:new tools for analysis of hepatic fi-brosis[J].Gut, 2005, 54:142-151.
|
[2]肖柳英, 林培英, 张丹, 等.青蒿琥酯对小鼠肝癌及S180实体瘤的抑制作用[J].实用癌症杂志, 200l, 16 (3) :245-247.
|
[3] 杨联萍, 马力, 张淑莲, 等.青蒿琥酯抗乙型肝炎病毒体外实验研究[J].实用临床医学, 2004, 18 (1) :1-2.
|
[4]Romero MR, Efferth T, Serrano MA, et al.Effect of arte-misinin/artesunate as inhibitors of hepatitis Bvirus produc-tion in an“in vitro”replicative system[J].Antiviral Res, 2005, 68 (2) :75-83.
|
[5]方步武, 来丽娜, 林雅军, 等.青蒿琥酯抗四氯化碳致大鼠肝纤维化的作用[J].中国药理学通报, 2005, 2 (6) :381-382.
|
[6]刘金元, 杨冬娣.青蒿琥酯对肝纤维化小鼠肝细胞内CA2+分布的影响[J].新中医, 2010, 42 (1) :108-109.
|
[7]吉明柱, 张永健.灯盏细辛治疗肝硬化的临床研究[J].交通医学, 2006, 20 (3) :267-269.
|
[8]陈咏萍.灯盏花素对肝硬化微循环和纤维化指标的影响[J].黑龙江医药科学, 2006, 23 (5) :10.
|
[9]杜钢军, 王梅, 林海红, 等.灯盏花素的肝纤维化保护作用[J].河南大学学报, 2009, 28 (3) :170-176.
|
[10]王晓东, 刘永忠, 刘永刚.红景天苷体外抗肝纤维化的实验研究[J].时珍国医国药, 2004, 15 (3) :138-139.
|
[11]王晓东, 刘永刚, 苏薇薇.红景天苷对小鼠实验性肝损伤的保护作用[J].中药材, 2004, 27 (3) :198-199.
|
[12]周杨, 顾杰, 徐列明.丹参酚酸B盐抑制内皮素-1所致大鼠门静脉压力升高的药效及其作用机制[J].中西医结合学报, 2007, 5 (1) :61-64.
|
[13]张杰, 张文炜, 徐列明.丹参酚酸B盐对内皮素诱导的人肝星状细胞收缩的抑制作用及机制研究[J].中国中西医结合杂志, 2009, 29 (1) :60-64.
|
[14]孙自勤, 王要军, 权启镇, 等.汉防已甲素与秋水仙碱抗肝纤维化作用的比较[J].中国药理学通报, 1996, 12 (4) :345-347.
|
[15]田字彬, 刘思良, 李定国, 等.防己甲素对血小板衍生生长因子促细胞增殖效应的阻断作用[J].中华医学杂志, 1997, 77 (1) :50-53.
|
[16]李定国, 陆汉明, 陈颖伟.汉防己甲素抗肝纤维化研究进展[J].世界华人消化杂, 1999, 7 (2) :171-172.
|
[17]柏长青, 宋颖芳, 王德堂, 等.黄芪、党参提取物抑制肺癌细胞诱导血管内皮细胞迁移的实验研究[J].武警医学, 2008, 6 (19) :505-506.
|
[18]李淑萍, 许晓燕, 孙箴, 等.黄芪多糖和黄芪总甙调控LX-2细胞因子分泌[J].浙江大学学报, 2007, 36 (6) :545-547.
|
[1] | Gao YuDi, Tian Yuan, Zhang XiangYing, Zhang XiaoHui, Duan ZhongPing, Ren Feng, Chen Yu. Effect of magnesium isoglycyrrhizinate on concanavalin A-induced acute liver failure in mice[J]. Journal of Clinical Hepatology, 2020, 36(7): 1571-1576. doi: 10.3969/j.issn.1001-5256.2020.07.024 |
[2] | Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028 |
[3] | Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases. Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(5): 844-852. doi: 10.3969/j.issn.1001-5256.2016.05.004 |
[4] | Li XiaoHui, Wen Yu, Jin WenHui, Hong Zhuan, Ceng MeiYan, Chen WeiZhu. Compatible stability of magnesium isoglycyrrhizinate injection and reduced glutathione for injection[J]. Journal of Clinical Hepatology, 2016, 32(1): 143-147. doi: 10.3969/j.issn.1001-5256.2016.01.028 |
[5] | Li XiaoPeng, Li Ming, Lei Wan, Zhang LunLi. Protective effect of magnesium isoglycyrrhizinate in rats with acute liver failure induced by D- galactosamine[J]. Journal of Clinical Hepatology, 2016, 32(3): 545-548. doi: 10.3969/j.issn.1001-5256.2016.03.032 |
[6] | Mao HaiYing, Kang Tao, Yao Ling, Chen Qin. Efficacy of glycyrrhizin in patients with chronic severe hepatitis B:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 63-67. doi: 10.3969/j.issn.1001-5256.2015.01.014 |
[7] | Ji HuiChun, Liu QingDe, Wang HongQi, Li Juan, Zhu Yun, Sun Yang, Zhou ZhongHai, Liu JunQuan. Clinical efficacy of puerarin combined with compound ammonium glycyrrhetate S in treatment of alcoholic hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1067-1070. doi: 10.3969/j.issn.1001-5256.2014.10.023 |
[8] | Wang XiaoPeng, Su He, Tian HongWei, Zhang SuYu, Wu ZiYan, An YaLi, Ma YunTao. Clinical efficacy of magnesium isoglycyrrhizinate in treatment of liver injury among patients with obstructive jaundice after percutaneous transhepatic cholangiodrainage[J]. Journal of Clinical Hepatology, 2014, 30(6): 563-566. doi: 10.3969/j.issn.1001-5256.2014.06.022 |
[9] | Luo XiaoKe, Li XiaoLing, Yang LiMing, Wang XiaoHong. Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2014, 30(6): 537-539. doi: 10.3969/j.issn.1001-5256.2014.06.014 |
[10] | Xu ZhongNan, Wu XiMing, Wang Pei, Zhang XiQuan, Xia ChunGuang, Wang XunQiang, Wang Yang, Zhan XiaoLe, Qu Ying, Xu MingYi, Lu LunGen. 18α glycyrrhizic acid in the treatment of acute liver injury induced by D-galactosamine in rats[J]. Journal of Clinical Hepatology, 2012, 28(1): 63-65+70. |
[11] | Jing XiaoZhen, Liu Jing, Qian Hai. The therapeutic efficacy of magnesium isoglycyrrhizinate on rats with non alcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2011, 27(3): 295-297. |
[12] | Suo HaiFen, Zhu YaoJu. Effect of sophocarpidine and diammonium glycyrrhizinate injection on hepatic fibrosis and the content of interferon-γ of chronicity type B Hepatitis patients[J]. Journal of Clinical Hepatology, 2010, 26(2): 196-198. |
[16] | Li YunRu, Wang WenBing, Zhang LiYing, Ou YuNi, Xie Wen, Wei Lai. The analysis of efficacy of glycyrrhizin therapy for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 117-118. |
[18] | Yin HeKun, Li QiXiang, Luo Dan. The clinical study of L-ornithine-L-aspartate combined with SNMC for hepatic encephalopathy of liver cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 268-269. |
[20] | Li YongXin, Gao QingWei, Wang YingLan. Analysis on clinical efficacy of Thiamine and Drammonium glycyrrhizinate concerning the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2003, 19(4): 226-227. |